Claritev Corporation’s (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation (NYSE:CTEV) shares have continued their recent momentum with a 25% gain in the last month alone. The last 30 days were the cherry on top of the stock’s 332% gain in the last year, which is nothing short of spectacular.
Although its price has surged higher, Claritev may still be sending buy signals at present with its price-to-sales (or “P/S”) ratio of 0.9x, considering almost half of all companies in the Healthcare Services industry in the United States have P/S ratios greater than 2.8x and even P/S higher than 7x aren’t out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it’s justified.
